STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – CTG, TMBR, HEP, CEQP
21. August 2023 17:33 ET
|
Monteverde & Associates PC
NEW YORK, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national...
Timber Pharmaceuticals Receives European Orphan Designation for Autosomal Recessive Congenital Ichthyosis & Positive Comments on Pediatric Investigation Plan for TMB-001 in Autosomal Recessive CI & X-Linked Recessive Ichthyosis
25. Oktober 2022 08:00 ET
|
Timber Pharmaceuticals
- Regulatory Milestones Improve Path to Filing a European Marketing Authorization Application -- Company Plans to Submit Additional Application for Orphan Designation in Europe for TMB-001 for the...
Timber Pharmaceuticals to Present at the Virtual Summer Summit
03. Juni 2020 08:00 ET
|
Timber Pharmaceuticals
Presentation on Tuesday, June 9th at 2:10pm ET WOODCLIFF LAKE, NJ, June 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE...